Brimonidine Tartrate (13 brand names, 4 dosage forms, 2 routes)
Available dosage forms: SOLUTION/DROPS, SUSPENSION/DROPS, SOLUTION, GEL.
Routes of administration: OPHTHALMIC, TOPICAL.
Brand Names
- ALPHAGAN
- ALPHAGAN P
- BRIMONIDINE TARTRATE
- BRIMONIDINE TARTRATE AND TIMOLOL MALEATE
- BRIMONIDINE TARTRATE; TIMOLOL MALEATE
- BRINZOLAMIDE; BRIMONIDINE TARTRATE
- COMBIGAN
- LUMIFY
- LUMIFY PRESERVATIVE FREE
- MIRVASO
- QOLIANA
- SIMBRINZA
- YUVEZZI
Indications and Usage
Brimonidine tartrate ophthalmic solution 0.1% is indicated for the reduction of elevated intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension.
Dosage and Administration
The recommended dosage is one drop of brimonidine tartrate ophthalmic solution 0.1% in the affected eye(s) three times daily, approximately 8 hours apart. Brimonidine tartrate ophthalmic solution 0.1% may be used concomitantly with other topical ophthalmic drug products to lower intraocular pressure. If more than one topical ophthalmic product is to be used, the different products should be instilled at least 5 minutes apart.
Adverse Reactions
The following serious adverse reactions are described elsewhere in the labeling: Potentiation of Vascular Insufficiency [see Warnings and Precautions ( 5.1)] Severe Cardiovascular Disease [see Warnings and Precautions ( 5.2)] Contamination of Topical Ophthalmic Products after Use [see Warnings and Precautions ( 5.3)] Neonates and Infants (Pediatric Patients Younger than 2 Years Old) [see Contraindications ( 4.1)]
Mechanism of Action
Brimonidine tartrate ophthalmic solution 0.1% is a relatively selective alpha-2 adrenergic receptor agonist with a peak ocular hypotensive effect occurring at two hours post-dosing. Fluorophotometric studies in animals and humans suggest that brimonidine tartrate has a dual mechanism of action by reducing aqueous humor production and increasing uveoscleral outflow.
Overdosage
Limited information exists on accidental ingestion of brimonidine in adults; the only adverse reaction reported to date has been hypotension. Symptoms of brimonidine overdose have been reported in neonates, infants, and children receiving brimonidine tartrate ophthalmic solution 0.1% as part of medical treatment of congenital glaucoma or by accidental oral ingestion [see Use in Specific Populations ( 8.4)] . Treatment of an oral overdose includes supportive and symptomatic therapy; a patent airway should be maintained.